Improvement of Women's Health After Allogeneic Stem Cell Transplantation
- Conditions
- GVHD, Chronic
- Registration Number
- NCT06279676
- Lead Sponsor
- Ciusss de L'Est de l'Île de Montréal
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not yet recruiting
- Sex
- Female
- Target Recruitment
- Not specified
Inclusion Criteria:<br><br> - All women aged 18 and over who will receive a first allogeneic HSCT (bone marrow,<br> peripheral blood stem cells from a related, unrelated (including cord blood) or<br> haploidentical donor) at the CIUSSS-EMTL. Recruitment will begin when the project<br> receives ethical approval. Recruitment period will be of 2 to 3 years.<br><br>Exclusion Criteria:<br><br> 1. Those who receive a second HSCT allograft.<br><br> 2. Those who receive an autologous transplant.<br><br> 3. Inability to give informed consent.<br><br> 4. Unable to communicate in French or English.<br><br> 5. Any other reason which, according to the investigators, makes it preferable for a<br> patient not to participate.
Not provided
Study & Design
- Study Type
- Observational [Patient Registry]
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Define the incidence and describe clinical presentation of vulvovaginal cGVHD after allogeneic stem cell transplants reflecting modern transplant practice.
- Secondary Outcome Measures
Name Time Method Evaluate genital cGVHD treatment response;Evaluate the frequency of premature ovarian failure;Measure the incidence and prevalence of HPV infection;Evaluate the quality of life (QoL) of allografted women;Evaluate intimacy within relationships of allografted women;Evaluate sexual function of allografted women;Evaluate sexual distress of allografted women